Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NEOAVAX
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
- NCT03341845 ↗
- Unknown
- The Netherlands Cancer Institute
- Standard
We haven't built an HCP commentary report on NEOAVAX (axitinib plus avelumab in localized clear-cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NEOAVAX so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Renal Cell Carcinoma
- Interventions
- Axitinib; Avelumab
- Arms
- axitinib and avelumab · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- number of patients with partial remission
- Sponsor
- The Netherlands Cancer Institute with Pfizer
- Start
- Mar 28, 2018
- Primary completion
- Jan 31, 2023 (estimated)
- Results posted
- No
- Registry record
- NCT03341845 · updated May 21, 2018
Publications
linked from the registry- Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, Lagerveld B, Zondervan P, van Moorselaar JA, Blank C, Wilgenhof S, Haanen J. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). Future Oncol. 2019 Jul;15(19):2203-2209. doi: 10.2217/fon-2019-0111. Epub 2019 Apr 26. PubMed 31023100